التفاصيل البيبلوغرافية
| العنوان: |
Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients. |
| المؤلفون: |
Zhou, Sarah, Sikorski, Daniel, Xu, Honghao, Zubarev, Andrei, Chergui, May, Lagacé, François, Miller Jr., Wilson H., Redpath, Margaret, Ghazal, Stephanie, Butler, Marcus O., Petrella, Teresa M., Claveau, Joël, Nessim, Carolyn, Salopek, Thomas G., Gniadecki, Robert, Litvinov, Ivan V., Moulin, Alexandre, Michielin, Olivier |
| المصدر: |
Cancers; May2021, Vol. 13 Issue 9, p2282-2282, 1p |
| مصطلحات موضوعية: |
GENETIC mutation, ONCOGENES, MELANOMA, METASTASIS, MEDICAL protocols, TREATMENT delay (Medicine), CELLULAR signal transduction, GENETIC markers, DECISION making, GENETIC techniques, TUMOR markers, DECISION making in clinical medicine, MITOGEN-activated protein kinases, SYMPTOMS |
| مصطلحات جغرافية: |
EUROPE, CANADA, UNITED States |
| مستخلص: |
Simple Summary: Reflex molecular testing is an emerging concept in oncology that, for a variety of cancers, was demonstrated to reduce the time to treatment initiation, thus potentially impacting survival outcomes. In advanced melanoma, BRAF mutation testing is critical in predicting treatment response with targeted therapy (i.e., BRAF/MEK inhibitors). Certain features were identified in melanomas that harbor BRAF mutations (e.g., primary lesions located on the trunk, diagnosed in patients <50, visibly pigmented tumors and, at times, with ulceration or specific dermatoscopic features). For select advanced melanoma patients, delays in determining mutational status present a significant barrier to the prompt initiation of treatment, which can adversely impact patient outcomes, especially in the metastatic setting due to a rapidly progressive disease. Treatment in these cases needs to start promptly by a medical oncologist. Ordering BRAF testing by preceding members of the treating team will allow medical oncologists to initiate treatment at the first visit. According to poor survival outcomes, we propose that patients with thick tumors (>4.0 mm) or >2 mm tumors with ulceration (i.e., stage ≥IIB) should potentially be considered for systemic therapy, thus justifying reflex BRAF testing. We overview current BRAF mutation testing recommendations and methods used in the United States, Canada, and Europe. Targeted therapy has been developed through an in-depth understanding of molecular pathways involved in the pathogenesis of melanoma. Approximately ~50% of patients with melanoma have tumors that harbor a mutation of the BRAF oncogene. Certain clinical features have been identified in BRAF-mutated melanomas (primary lesions located on the trunk, diagnosed in patients <50, visibly pigmented tumors and, at times, with ulceration or specific dermatoscopic features). While BRAF mutation testing is recommended for stage III–IV melanoma, guidelines differ in recommending mutation testing in stage II melanoma patients. To fully benefit from these treatment options and avoid delays in therapy initiation, advanced melanoma patients harboring a BRAF mutation must be identified accurately and quickly. To achieve this, clear definition and implementation of BRAF reflex testing criteria/methods in melanoma should be established so that patients with advanced melanoma can arrive to their first medical oncology appointment with a known biomarker status. Reflex testing has proven effective for a variety of cancers in selecting therapies and driving other medical decisions. We overview the pathophysiology, clinical presentation of BRAF-mutated melanoma, current guidelines, and present recommendations on BRAF mutation testing. We propose that reflex BRAF testing should be performed for every melanoma patient with stages ≥IIB. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder